Ibuprofen is widely used throughout the world for a variety of conditions. This reference work provides a comprehensive and critical review of the basic science and clinical aspects of the drug. The book begins with the history and development of the drug and its current patterns of use world- wide before moving on to examine its basic pharmaceutical attributes and medicinal chemistry. The properties of various formulations are described (oral prescription and OTC, topical and others) are described. The pharmacokinetics of ibuprofen in animals and humans is discussed - highlighting the factors affecting absorption, distribution, metabolism and elimination. The clinical pharmacology and toxicology and the drug's mechanisms of action in different disease states and conditions are covered. The therapeutic uses in various acute and inflammatory conditions is detailed. Also considered are the safety versus efficacy issues and the pharmacoepidemiological data.
Table of Contents
1. History and Development of Ibuprofen K.D. Rainsford 2. The Medicinal Chemistry of Ibuprofen K.J. Nichol 3. The Pharmaceutics of Ibuprofen F. Higton 4. The Pharmacokinetcs of Ibuprofen in Humans and Animals D.R. Brocks and F. Jamaili 5. Pharmacology and Toxicology of Ibuprofen K.D. Rainsford 6. Therapeutics of Ibuprofen in Rheumatic and Other Chronic and Painful Diseases W.F. Kean, W.W. Buchanan and K.D. Rainsford 7. Safety and Efficacy of Non-Prescription (OTC) Ibuprofen K.D. Rainsford 8. Use of Ibuprofen in Dentistry R.A. Dionne and S.A. Cooper 9. Gastrointestinal Adverse Drug Reactions Attributed to Ibuprofen D.A. Henry, A. Drew and S. Beuzeville 10. Renal Effects of Ibuprofen M.D. Murray and D.C. Brater 11. Adverse Drug Reactions Attributed to Ibuprofen: Effects Other Than Gastrointestinal L.J. Miwa and J.K. Jones 12. Human Toxicity of Ibuprofen G.N. Volans and R. Fitzpatrick Nichol, Boots Pharmaceuticals, UK, F. Higton, Boots Healthcare International, D.R. Brock, Western University of Health Sciences, USA, F. Jamaili, University of Alberta, USA, W.F. Kean, McMaster University, Canada, W.W. Buchanan, Sir William Osler Health Institute, Canada, R.A. Dionne, National Istitute of Health, USA, S.A. Cooper, Whitehall-Robins Health Care, USA, D.A. Henry, Newcastle Mater Hospital, Australia, A. Drew, Newcastle Mater Hospital, Australia, S. Beuzeville, Newcastle Mater Hospital, Australia, M.D. Murray, Regenstrief Health Centre, USA, D.C. Brater, Indiana university School of Medicine, USA, L.J. Miwa, The Degge Group, USA, J.K. Jones, The Degge Group, USA, G.N. Volans, Guys and St. Thomas' Hospital Trust, UK, R. Fitzpatrick, Guys and St. Thomas' Hospital Trust, UK.
Kim Rainsford is Professor and Chair of Biomedical Sciences and Director of the Biomedical Research Centre at Sheffield Hallam University, UK. His research interests lie mainly in mechanisms of inflammation and the mode of action of anti-inflammatory and anti-arthritic drugs. He has published many books and journal articles and is frequently invited to speak at major international conferences and meetings.